Seeking Alpha

Galectin Therapeutics: Neutral On Belapectin For NASH Cirrhosis Amid Financial Challenges

Galectin Therapeutics is focused on developing therapies that target galectin proteins related to conditions such as metabolic dysfunction-associated steatohepatitis, cirrhosis, and cancer. Its ...
Acsh.org

A New Drug Offers Hope For A Common, Life-Threatening Liver Disease

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no current cure, but a drug called resmetirom may offer a lifeline for millions of patients, promoting a better quality of life ...
Seeking Alpha

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosis Noninvasive test data ...
Nasdaq

Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis

The FDA decision follows the Company’s Fast Track designation request for lanifibranor in NASH with compensated cirrhosis filed in August 2021 The FDA’s dedicated Fast Track program is designed to ...
Nasdaq

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

CONSHOHOCKEN, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic ...
Yahoo

FDA Approves First Fatty Liver Disease Drug: Who It’s For and How It Works

For those dealing with fatty liver disease, there’s welcome news to report. Earlier this year, the United States Food and Drug Administration (FDA) approved the first and only fatty liver disease drug ...
Hosted on MSN

New fatty liver disease treatment could save millions of people worldwide

Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a condition that affects billions worldwide. Their research has led to the ...
Business Insider

Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials

SAN DIEGO, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s completed ...
Hosted on MSN

FDA Approves First Fatty Liver Disease Drug: Who It's For and How It Works

For those dealing with fatty liver disease, there's welcome news to report. Earlier this year, the United States Food and Drug Administration (FDA) approved the first and only fatty liver disease drug ...